Skip to main content
. 2020 Sep 17;44(1):167–177. doi: 10.1007/s13402-020-00559-9

Fig. 2.

Fig. 2

Raloxifene suppresses IL-6 secretion and IL-6-induced STAT3 phosphorylation in L3.6pl pancreatic cancer cells. ELISA showing that IL-6 concentrations are reduced after 24 hours of raloxifene treatment at different concentrations (a) (* p < 0.05). Representative Western blots showing that raloxifene inhibits IL-6-induced STAT3 phosphorylation in L3.6pl cells in a dose- and time-dependent manner (b and c, respectively). DARTS assay showing protein-ligand interaction between raloxifene and gp130. SC144 is a known gp130 inhibitor and was used as a positive control. The affinity of raloxifene to gp130 was similar to that of SC144 at a pronase concentration of 1:10,000 (d)